



IFCC PRESIDENT ELECT NOMINATIONS

2020 - 2023

LIST OF CANDIDATES

Nominees

Khosrow Adeli

Päivi Laitinen

Tomáš Zima

National Society

Canadian Society of Clinical Chemists
(CSCC)

Finnish Society of Clinical Chemistry
(SKKY)

Czech Society of Clinical Biochemistry
(CSKB)





Khosrow ADELI

CANADIAN SOCIETY OF CLINICAL CHEMISTS
(CSCC)



NOMINATION FORM for PRESIDENT IFCC EXECUTIVE BOARD 2021-2023

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by National Society

On behalf of ...Canadian Society of Clinical Chemists.....
(insert name of National Society)

Name: Stephen Hill.....

Office held within the National Society:....President.....
(This should normally be the nominated National Representative to the IFCC Council)

**We nominate for the Office of President for the term 2021-2023
(to begin as President-elect in 2020):**

Dr. Khosrow Adeli.....
(insert name of nominee)

Signature:.....  ..

Date: ...2019-02-11.....

2. Acceptance by Nominee

I,Khosrow Adeli..... Date of Birth: ...March 21, 1953.....
(insert name)

accept nomination for election to the position of President
and accept the obligations and time commitment required for this position, if elected.


My contact details are:

Address: Clinical Biochemistry, Paediatric Laboratory Medicine
The Hospital for Sick Children, University of Toronto

Phone: ...416-813-8682...

Fax: ...416-813-6257...

Email: ...k.adeli@utoronto.ca...

Signature: ...  ..

Date: ...March 5, 2019.....

3. Details supplied by nominee

Please supply information for circulation to the National Societies. This should include details of previous service within IFCC, national or regional organisations; professional position(s) currently held and major professional, scientific or clinical interests; and a position statement outlining issues which you see as important for the IFCC and how you might address them. A full curriculum vitae is not required. As a guide, one page of single-spaced text should be sufficient.

Khosrow Adeli PhD, FCACB, DABCC, FAACC

Professor Adeli is currently the Head of Clinical Biochemistry at the Hospital for Sick Children and the Vice-Chair of Laboratory Medicine & Pathology at the University of Toronto in Toronto, Canada. He is also a senior scientist in Molecular Medicine at the Research Institute, The Hospital for Sick Children. He is very well known for his extensive national and international contributions over the past 30 years to clinical laboratory service, research, and education. He has also held several leadership positions nationally and internationally including:

- *Chair, IFCC Communications and Publications Division (2013-2018)
- *Chair, IFCC Public Relations Committee (2007-2012)
- *Board of Directors, American Association of Clinical Chemistry (AACC) Academy (2015-2018)
- *Editor-in-Chief, Critical Reviews in Clinical Laboratory Sciences (2013-present) (Impact Factor: 6.4)
- *Chair, Diabetes Grant Review Committee, Canadian Institutes of Health Research (CIHR) (2016-2019)
- *Scientific Advisory Board, International Centre in Genetic Engineering and Biotechnology (2009-2018)
- *President, The Commission on Accreditation in Clinical Chemistry (COMACC) (2007-2010)
- *Editor-in-Chief, Clinical Biochemistry (1999-2006)
- *Chair, Canadian Academy of Clinical Biochemistry (1999-2001)

The impact of Professor Adeli's contributions to the field of clinical chemistry and laboratory medicine have been profound and recognized through several national and international awards including:

- *2019 AACC Outstanding Research Award in Clinical Chemistry, American Association of Clinical Chemistry
- *2018 Hungarian Academy Honorary Award, Hungarian Academy of Laboratory Medicine
- *2016 CSCC Innovation Award in Laboratory Medicine, Canadian Society of Clinical Chemists
- *2015 AACC Pediatric-Maternal-Fetal Division Award, American Association of Clinical Chemistry
- *2015 OSCC Lifetime Achievement Award, Ontario Society of Clinical Chemists
- *2015 CSCC Outstanding Education Award, Canadian Society of Clinical Chemists
- *2014 Distinguished Service Award in Laboratory Medicine, University of Toronto
- *2014 CSATVB Scientific Excellence Award, Canadian Society of Atherosclerosis, Thrombosis, & Vascular Biology
- *2010 COMACC Service Award, The Commission on Accreditation in Clinical Chemistry
- *2006 CSCC Outstanding Contributions to Clinical Chemistry, Canadian Society of Clinical Chemists
- *2004 CACB Outstanding Contributions to Clinical Biochemistry, Canadian Academy of Clinical Biochemistry
(several other awards not listed)

Contributions to IFCC and its Membership: Professor Adeli recently completed a 12-year term on the IFCC Communications and Publications Division (CPD). He initially served as Vice-Chair and later as Chair over the past 6 years. CPD is responsible for all IFCC publications and communication activities including the eNews, eJournal, website, eAcademy/eLearning, and public relations activities. During his term as Chair, he worked closely with the CPD executive, committees, and working groups and played a leadership role in significantly enhancing publication and communication activities of the IFCC organization. Key achievements of CPD over the past 10 years include:

- *Creation of a new and much improved IFCC website (better design, functionality, user-friendliness, content)
- *Publication of a much improved IFCC newsletter, growing from 4 issues a year, to now almost monthly publications (11 issues published in 2018) with contributions from clinical chemistry societies around the world
- *Creation of a Public Relations (PR) Committee and a global PR campaign on value of lab medicine in healthcare
- *Successful indexing of the IFCC Electronic Journal (eJIFCC) in PubMed and significantly improved content in terms of both quality of published work and quantity of articles published annually
- *Development of an IFCC Mobile App to facilitate ready access to IFCC media
- *Development of a new eLearning program (the "IFCC eAcademy") to provide educational webinars worldwide
- *Expansion of a Spanish language communication initiative across Latin America (RIA [*Rincón Iberoamericano*] and DIV [*Diagnóstico in Vitro*] Magazine)

Professor Adeli has also directly interacted with and personally knows IFCC national representatives from dozens of countries around the world as well as corporate members. As a result of his IFCC contributions and research achievements, he has been invited to deliver numerous presentations to IFCC national societies and/or regional/international conferences in many countries including: Argentina, Australia, Brazil, China, Ecuador, France, Germany, Greece, Hungary, India, Indonesia, Iran, Italy, Korea, Mexico, Morocco, Netherlands, Paraguay, Philippines, Poland, Qatar, Russia, South Africa, Spain, Turkey, UAE and Uruguay. He has therefore developed strong relationships with many IFCC member societies as well as many IFCC officers within the IFCC organization.

Contributions to Research in Laboratory Medicine: In addition to his IFCC contributions, the basic and translational research in Professor Adeli's laboratory have been extremely productive and yielded a career total of 290 peer-reviewed full articles as well as hundreds of abstracts/conference presentations. The scientific impact of his work has been extensive, as evidenced by numerous citations to his publications (*Google Scholar Statistics: h-index of 68 and i10-index of 232, with over 21,000 citations*). Furthermore, he has personally delivered a total of 56 invited presentations since 2010 at national and international conferences or universities/research centers worldwide. One of his most significant contributions to the field of clinical chemistry has been in the area of reference intervals, leading to the development of the Canadian Laboratory Initiative on Pediatric Reference Intervals (CALIPER) (www.caliperproject.org). His original CALIPER studies have closed the evidence gaps in pediatric reference intervals with major global impact. Hundreds of clinical laboratories in the US, Canada, and in over 100 countries around the world currently use CALIPER pediatric reference intervals in their routine clinical practice.

Contributions to Education in Laboratory Medicine: In the area of education, Professor Adeli has been the Director of the Postdoctoral Training Program at the University of Toronto for over 20 years. He has directly mentored more than 50 clinical chemistry fellows, many of whom now hold prominent positions in laboratories across Canada, the US, and other countries. He also served (2006-2010) as the President of COMACC, the Commission on Accreditation in Clinical Chemistry, (a North American organization responsible for accreditation of clinical chemistry training programs in the US and Canada). In further recognition of his national and international contributions to education, Professor Adeli received the 2010 COMACC Leadership Award and the 2012 CSCC Education Award.

Personal Statement and Vision: I strongly feel that I can be very effective in this leadership position in light of my considerable experience with the IFCC organization, my numerous links to IFCC membership and member countries, as well as my productive track record during my term as IFCC division chair. I have over 30 years of experience in several senior leadership positions in the field of laboratory medicine within my own institution, my national clinical chemistry community, as well as internationally within IFCC and AACC. My accomplishments in all areas of clinical chemistry service, research, education, as well as outreach and communication, have prepared me well for such a position and would allow me to make important contributions to the IFCC's mission of "advancing excellence in laboratory medicine for better healthcare worldwide". I have the background and experience to drive further advancements in key areas of the IFCC's mission including scientific leadership in the field of lab medicine, global educational activities, and innovative communication strategies within and outside the field of lab medicine at an international level. ***I strongly believe that the IFCC organization is in a unique leadership position to:***

- 1) Continue to promote the value of laboratory medicine by gathering the evidence to demonstrate the value of lab medicine in clinical decision making and healthcare delivery, communicating this to the public and all stakeholders.
- 2) Become the leader in developing practice guidelines to ensure optimal application and utilization of diagnostic services and improved clinical decision making using IFCC's extensive and wide-ranging scientific expertise.
- 3) Develop innovative quality improvement strategies and disseminate the concept of total quality management and quality systems approach to clinical laboratories and national societies, particularly in developing countries.
- 4) Become the largest provider of free Distance Learning/eLearning in the field of laboratory medicine worldwide. Through the new eAcademy platform and its vast network of experts, IFCC can develop the most comprehensive database of eLearning programs to support education by its member societies particularly in developing countries.
- 5) Encourage and support a culture of innovation in the IFCC community and communicate technological and process innovations to laboratory scientists and physicians globally. In association with regional federations, member societies, young scientists and corporate members, ensure that IFCC is a driver of technological innovations such as artificial intelligence and machine learning, and their application in laboratory medicine.

The future holds considerable promise for the IFCC organization and its family of national societies and corporate members. I look forward to being part of the IFCC's continued journey towards global leadership in lab medicine, contributing to its most valuable mission of improving clinical decision making and better healthcare worldwide.



**CANADIAN SOCIETY
OF CLINICAL CHEMISTS**

**OFFICERS
2018 – 2019**

PRESIDENT
Stephen Hill

PRESIDENT-ELECT
Edward Dunn

SECRETARY
Jennifer Shea

TREASURER
Ivan Blasutig

COUNCILLORS
Anna Fuezery
Danijela Konforte
Nicolas Tétreault

DIVISION HEADS
Education & Scientific
Affairs
Allison Venner

Professional Affairs
Julie Shaw

Publications
Isolde Seiden-Long

EXECUTIVE DIRECTOR
Pamela Lyons

▼
CSCC 2019
63rd Annual Meeting

June 2-5, 2019
Saint John NB
▲

Head Office
4 Cataragui Street
Suite 310
Kingston ON K7K 1Z7
Tel 613.531.8899
Fax 613.531.0626
office@csc.ca
www.csc.ca

2019-03-25

Dr. Graham Beastall, Chair
IFCC Nominations Committee
IFCC@IFCC.org

Dear Dr. Beastall,

Re: Dr. Khosrow Adeli

It is my pleasure, on behalf of the Canadian Society of Clinical Chemists, to nominate Dr. Khosrow Adeli as President of the IFCC.

Dr. Adeli is the Head of Clinical Biochemistry at the Hospital for Sick Children and Professor of Pathology and Laboratory Medicine at the University of Toronto. He has served the Federation in several leadership positions. I am certain that he would serve the Federation well as President.

The required documents are attached. Please contact me if further information is required.

Sincerely

Stephen Hill PhD, FCACB
President, Canadian Society of Clinical Chemists

Copies
P. Lyons, Executive Director
Jennifer Shea, Secretary
Ted Dunn, President Elect



Päivi LAITINEN

**FINNISH SOCIETY OF CLINICAL CHEMISTRY
(SKKY)**



NOMINATION FORM for PRESIDENT IFCC EXECUTIVE BOARD 2021-2023

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by National Society

On behalf ofFinnish Society of Clinical Chemistry.
(insert name of National Society)

Name:.....Anna Linko-Parvinen.....

Office held within the National Society:President.....
(This should normally be the nominated National Representative to the IFCC Council)

**We nominate for the Office of President for the term 2021-2023
(to begin as President-elect in 2020):**

Päivi Laitinen

.....
(insert name of nominee)

Signature:...

Date:April 10, 2019.....

2. Acceptance by Nominee

Päivi Laitinen..... Date of Birth:July 28, 1955
(insert name)

accept nomination for election to the position of President

and accept the obligations and time commitment required for this position, if elected.

My contact details are:

Address: ... HUSLAB.....
..... PO Box 720, Topeliuksenkatu 32, 00029 HUS.....
..... Finland.....

Phone:+358 505499 622.....

Fax:

Email:paivi.h.laitinen@hus.fi.....

Signature:...

Date:April 9, 2019.....

3. Details supplied by nominee

Please supply information for circulation to the National Societies. This should include details of previous service within IFCC, national or regional organisations; professional position(s) currently held and major professional, scientific or clinical interests; and a position statement outlining issues which you see as important for the IFCC and how you might address them. A full curriculum vitae is not required. As a guide, one page of single-spaced text should be sufficient.

Päivi Laitinen is Chief Chemist in HUSLAB, Laboratory of Helsinki University Hospital and in that role she is responsible of the technical and analytical issues as well as acquisitions of Clinical Chemistry and Pre-analytical Services of HUSLAB.

Päivi Laitinen obtained her PhD in Biochemistry and Master's degree in Health Care Administration at Oulu University. Her scientific interests focus presently mainly on the use and implementation of cardiac markers. At the moment she chairs an EFLM Task Group Cardiac Markers. She has published about 50 peer-reviewed articles.

Päivi Laitinen has been actively involved in the activities of the scientific societies of clinical chemistry and laboratory medicine at the international, European and national level. Päivi Laitinen served as Secretary of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Executive Board in 2006-2011. She has also been a member of the IFCC Awards Committee (2003-2005), Chair and Past Chair of Nominations Committee (2012-2017). The international activities include memberships of the European Communities Confederation of Clinical Chemistry (EC4) Board (2003-2005) and Scandinavian Society of Clinical Chemistry Board (1998-2002). Päivi Laitinen has been an active member of the Finnish Society of Clinical Chemistry since 1987 and served as President of the Society in 1998-2002. She has been a member of the Finnish Clinical Chemistry Register Committee (EC4) 1998-2002, and a member of the Working Group on Laboratory Nomenclature of the Finnish Union of Counties 1999-2013.

Position statement:

Clinical laboratories have faced enormous changes during the past decades. We have experienced the transfer from manual methods of small local laboratories to huge total automation laboratories which handle thousands of sample tubes a day. At the same time the quality of methods has improved dramatically, mainly due to the standardization efforts of IFCC and IVD industry. Accreditation of clinical laboratories has improved the documentation and processes of laboratories. The emphasis has been on the quality of laboratory services as well as handling of the growing volume of services. I think IFCC must look into the future showing the real value of laboratory services and take the global leadership in this role. This can be achieved by collaboration with clinical associations as well as with IVD industry in all levels, local, national, regional and international. This is a joint effort.

IFCC is the leading scientific organization in the field of laboratory medicine. In this role IFCC should focus on the following:

1. The high quality of laboratory services is essential for the whole healthcare and impacts patient safety. The main focus of IFCC has been in the standardization and harmonization as well as traceability of laboratory tests, which are the key components of high quality laboratory services. I believe this remains to be backbone of IFCC activities. Laboratories also need to improve their processes in order to meet the increasing demands of patient care. This means that we need to do more, we need to do it faster with less budget. We need tools for following the key performance indicators of processes and for this data mining we need laboratory information systems. I think IFCC should take a leading role in advancing these activities.

2. Clinical laboratories have been considered to be merely service providers and not equal partners in healthcare. IFCC has taken steps into showing evidence of the value of laboratory medicine as part of healthcare and we need to continue this effort in collaboration with clinical associations and patient organizations. We make difference! I believe IFCC can take a key role in this collaboration.

3. Patient care is guided by international and national guidelines. These guidelines are often written without participation of laboratory professionals. There is evidence that these guidelines are not always followed by laboratories. I think IFCC should seek collaboration with clinical associations in writing these guidelines in a way that the methods used and laboratory processes are considered.

4. IFCC has now 92 Full Members. IFCC should seek new members (Full and Affiliate), especially among emerging nations and other societies of laboratory medicine. I believe new companies, like IT companies should be considered as Corporate Members.

5. Today environment is a concern of all people. Laboratory activities have impact on environment due the use of electricity, water and production of waste etc. Laboratories can do a lot to reduce, reuse and recycle. I think IFCC should take a leadership role in guiding laboratories for sustainability. IFCC should also seek ways of considering environment when planning its meetings, congresses and conferences.

As President of IFCC I shall focus on the activities on improving the quality of laboratory services and collaboration between IFCC and clinical associations and patient organizations. The next Executive Board needs to focus on the sustainability of IFCC activities and laboratories. I shall also strengthen the collaboration between IFCC officials in Divisions, Committees, Working Groups and Task Forces as well as national societies and corporate members.

Päivi Laitinen
Chief clinical chemist/ PhD, Adjunct Professor, EuSpLM



Suomen Kliinisen Kemian Yhdistys
Föreningen för Klinisk Kemi i Finland

10th April 2019 Turku, Finland

To whom it may concern,

Please find enclosed our nomination for the IFCC President/IFCC Executive Board (EB) for the term 2021-2023. We kindly propose chief chemist, adj. prof. Päivi Laitinen for the position.

Her primary scientific interests are with the use and implementation of cardiac markers and she has circa 50 peer-reviewed scientific papers.

Päivi Laitinen has been an active and enthusiastic member in the national and international societies, including IFCC, where she has served in several positions. She has wide international connections, and she is eager to develop the work of the IFCC. The application form describes her work and position statement in detail.


Dr. Päivi Laitinen is fully eligible for the position. The board of the Finnish Society of Clinical Chemistry fully supports Päivi Laitinen for the position of the IFCC president.

On behalf of the Finnish Society of Clinical Chemistry,

A handwritten signature in blue ink, appearing to read 'Anna Linko-Parvinen', is enclosed in a thin black rectangular box.

Anna Linko-Parvinen

MD, Ph.D.
President of Finnish Society of Clinical Chemistry
Turku University Hospital
Laboratory of Hematology
Turku, Finland
tel. +358405598212
e-mail. anna.linko-parvinen@tyks.fi



Tomáš ZIMA

**CZECH SOCIETY OF CLINICAL BIOCHEMISTRY
(CSKB)**



NOMINATION FORM for PRESIDENT IFCC EXECUTIVE BOARD 2021-2023

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by National Society

On behalf of The Czech Society of Clinical Biochemistry
(insert name of National Society)

Name: Richard Pikner, MD

Office held within the National Society: National Representative to the IFCC
(This should normally be the nominated National Representative to the IFCC Council)

**We nominate for the Office of President for the term 2021-2023
(to begin as President-elect in 2020):**

Professor Tomas Zima
(insert name of nominee)

Signature: 

Date: April 10, 2019

2. Acceptance by Nominee

I, Tomáš Zima
Date of Birth: July 2, 1966
(insert name)

accept nomination for election to the position of President

and accept the obligations and time commitment required for this position, if elected.

My contact details are:

Address:
Institute of Medical Biochemistry and Laboratory Medicine
The First Faculty of Medicine, Charles University and General
University Hospital, Prague
U Nemocnice 2
CZ 128 08 Prague 2
Czech Republic

Phone: + 420 603 720 759

Fax: + 420 22496 2848

Email: zimatom@cesnet.cz

Signature:  Date: April 10, 2019

3. Details supplied by nominee



The Czech Society of Clinical Biochemistry would like to nominate Professor Tomas Zima for the position of IFCC President. Professor Zima's career in laboratory medicine and clinical biochemistry started in early 1990s. He is the leading person in clinical biochemistry and laboratory medicine in the Czech Republic and a very active specialist in laboratory medicine world-wide.

Professor Tomas Zima, MD, DSc. Dr.h.c. (b. 1966) has been graduated at the First Faculty of Medicine, Charles University, Prague in 1990; he was appointed as **Professor of Medical Chemistry and Biochemistry in 2001**. He is the Head of Institute of Medical Biochemistry and Laboratory Medicine of the First Faculty of Medicine, Charles University and General University Hospital, Prague. He is a specialist in clinical chemistry, internal medicine and nephrology and registered as European Specialist in Laboratory Medicine (EuSpLM). He is also Master of Business Administration – Prague International Business School (2003). He acted as Dean of the First Faculty of Medicine, Charles University in the years 2005–2012. Now he is Rector of Charles University, Prague (II/2014–I/2022).

His main research interests include oxidative stress, AGE's, experimental nephrology, tumor markers, prenatal screening, laboratory management and accreditation. He authored/co-authored more than 450 scientific articles (which are quoted more than 3600 times according SCI, H-index is 31), 9 books and 72 chapters in books. He delivered more than 150 lectures abroad, he is a member of consortium EU project FAIR-PARK II – Conservative iron chelation as a disease-modifying strategy in Parkinsons disease – N-EUDRACT 2015-003679-31 and Next generation sepsis diagnosis - Grant Agreement number: 687697 – SMARTDIAGNOS – H2020-ICT-2015/H2020-ICT-2015.

Professor Zima has long term **teaching experience** in field of biochemistry, medical chemistry, pathobiochemistry, clinical chemistry and laboratory medicine. He is a member of Board for PhD studies in biochemistry and pathobiochemistry. He is the tutor of 11 PhD students, 10 of them have successfully finished their studies.

Professor Zima is a member of many **learned and scientific societies** (Academia Europea, Czech Medical Academy, The Learned Society of the Czech Republic) and serves in their boards (e.g. Czech Medical Association of J. E. Purkyne – member of praesidium since 2011, Scientific Board of Grant Agency of Czech Republic – chair in 2010–2014, Federation of European Biochemical Societies (FEBS) – chair of Executive Committee in 2011 and member – Education Committee 2012–2015). He worked in Alliance for Biomedical Research in Europe – European Council for Health Research - a member Core Working Group (2011–2012) and he has been a member of the European Commission's Scientific Panel for Health (SPH) since 2014. He is the Editor in Chief of scientific journals *Folia Biologica* and *Addictology* and a member of **editorial boards** of many scientific journals. He gained numerous awards in the Czech Republic (prizes of Czech Society of Clinical Chemistry, the prize of Praesidium of Czech Medical Association for monography Laboratory diagnostics) and also abroad among which, Professor Honoris Causa, State Medical University JY. Horbachevski in Ternopol (Ukraine), ESBRA Peter Berner Award (2011), doctor honoris causa – Uzhorod National University – Ukraine (2016), and Prešov University in biological sciences – Slovakia (2016).

Professor Zima has been intensively serving in field of **clinical chemistry and laboratory medicine** on national and international level for more than 20 years in positions:

- The Czech Society of Clinical Biochemistry – President 2006-2014, member of board from 2014;
- EFLM – European Federation of Clinical Chemistry and Laboratory Medicine: – member at large of Executive Board 2011–2019, member of Congresses and Postgraduate Education Working Group (WG-CPE) 2010–2012, member of EFLM Speakers Bureau;
- IFCC – Committee on Conferences and Congresses – corresponding member (2009–2013), full member from 2014, Registered expert IFCC;
- American Association for Clinical Chemistry – member since 2000.

Professor Zima participated in organization of congresses as a member of Congress Organizing Committee (Worldlab Istanbul 2014, Euromedlab Athens 2017, Munich 2021) and as a member of International Scientific Advisory Board of many scientific congresses and co-founder and organizer of CELME 2015, 2017, 2019.

Tomas Zima's main successful effort is in building links in Society between physicians, scientists and technicians, in medical school between theoretical and clinical subjects, and in university between science, medicine and humanities. For many years he engaged bilateral contacts with health stakeholders to share information and to enhance our profession and its role in the coordinated healthcare pathways.

The times ahead of lab medicine is exciting and challenging. Successful IFCC leadership includes the ability to create a clear vision, to share a deontological framework and ethical values, as well as the ability to innovate, the ability to focus on performance development, and the ability to encourage innovation.

Building links, better communication and sharing the best practices and innovation in health is an urgent need in IFCC between the regional organizations – continents and also among the professional groups in our profession among academy and industry professionals. We all need to work together closely with other partners – patients, corporates, society and stakeholders. Medicine at the beginning of the 21st century is patients centered using highly automated and connected diagnostic systems with balance of POCT or NPT.

In the very complex world of healthcare, AI tools can support lab professionals to provide faster service, diagnose issues and analyse data to identify trends or genetic information that would predispose someone to a diseases. AI and machine learning can be transformative not only for healthcare but for every single patient. New emerging technologies including – biochips, nanotechnology, digital pathology, and new trends in molecular biology will be more implemented in daily laboratory practice.

We live in a **digital world**, which will have more and more influence on our daily laboratory life, which include – new type of communication between us but mainly with our patients – mobile health. Integration care and medical data “big data” is a great challenge and an opportunity, as well as ethical aspects and data security and protection.

Tomas Zima's priorities for growing and developing IFCC is to make IFCC the real flagship organization in the field of laboratory medicine in incorporating emerging technologies (omics, precision medicine) and to establish or boost links and cooperation with the clinical associations, international institutions, industry (pharma, biomedical devices, information system, AI, etc); the main aim of all of us is to promote **added value of laboratory medicine**, to focus on patients centered medicine worldwide and better appreciation and importance of laboratory medicine in the society and the world as well.

IFCC, together with regional association, should be the leading force in **research in laboratory medicine** – value based, health centred, science led – with application to daily health care practice.

We should keep promoting on **standardization and harmonization** of laboratory medicine together with the corporates and regulatory bodies and on increasing the **quality system** - accreditation in laboratories, We take into account that laboratory medicine can improve the delivery of quality of care and **benefits for the well being, and of course, for patients and our staff safety**.

Our world is not developed on the same level as the whole and IFCC should **help and improve laboratory medicine in developing countries**.

The key role of IFCC is **education and training** of our professionals, other health care professionals and patients. We should put together our forces in all continents with exchange and developing new educational sources using modern platforms, e.g. hybrid conference model.

We should be more focused on and supportive for our future development – **the young scientists**.

We should continuously **improve the administrative work** of IFCC, its organizational structure and financial sustainability.

Our profession is **multifaced, diverse, different and interdisciplinary** – it is our challenge at communication with our clinical colleagues and between us.

The key role of the president of IFCC is to implement a more **proactive, transparent and operational strategy** to facilitate **the collaboration** with the regional associations and national societies – with the aim to do the best for laboratory medicine worldwide with people and for people.

To conclude, the Czech Society of Clinical Biochemistry is proud to nominate **Professor Tomas Zima** for the position of President of the IFCC for his excellent management abilities, laboratory, clinical, scientific, teaching and communication skills as highly suitable candidate for this position.



Czech Medical Association J. E. Purkyne

CZECH SOCIETY OF CLINICAL BIOCHEMISTRY

President:

Prof. Jaroslav Racek, MD, DSc.
Inst. Clin. Biochem. & Hematol.
Charles University Hospital
Alej Svobody 80
CZ-304 60 Pilsen
phone: +420 377 104 233
e-mail: racek@fnplzen.cz

Vice-President, IFCC Representative

Richard Pikner, MD, PhD
Department of Clinical Laboratories and
Bone Metabolism
Klatovy Hospital
Plzeňská 929
CZ-339 01 Klatovy
phone: +420 376 335 875
e-mail:
richard.pikner@klatovy.nemocnicepk.cz

Vice-President:

Assoc. Prof. Drahomira Springer, PhD
Inst. of Medical Biochemistry & Lab. Med.
First Faculty of Medicine Charles
University and General University Hosp.
U Nemocnice 2
CZ-128 08 Prague 2
phone: +420 224 962 883
fax: +420 224 962 848
e-mail: springer@vfn.cz

Secretary:

Pavel Malina, MD, PhD
Department of Clinical Biochemistry
Pisek Hospital
Karla Čapka 589
CZ-397 01 Pisek
phone: +420 382 772 120
e-mail: malina@nemopisek.cz

Treasurer:

Petr Kubáč, MD
Department of Clinical Biochemistry
City Hospital Ostrava
Nemocniční 20
CZ-728 80 Ostrava
phone: +420 725 500 657
e-mail: petr.kubac@mnof.cz

Member-at-Large:

Prof. Tomáš Zima, MD, DSc.
Inst. of Medical Biochemistry & Lab. Med.
First Faculty of Medicine Charles
University and General University Hosp.
U Nemocnice 2
CZ-128 08 Prague 2
phone: +420 224 962 841
fax: +420 224 962 848
e-mail: zimatom@cesnet.cz

Member-at-Large:

Dagmar Gotzmannová, PhD
Spadla Lab
Dr. Martinka 1491/7
CZ-700 30 Ostrava-Hrabůvka
phone: +420 724969324
e-mail: dagmar.gotzmannova@gmail.com

*Section of Laboratory Technicians -
chairman:*

Mgr. Martina Bunešová
Dept. Of Med, Chem & Clin. Biochem.
University Hospital Motol
V Úvalu 84
CZ-150 06 Prague 5
Phone : +420 224 435 318
Fax : +420 224 435 320
E-mail : bunesovam@seznam.cz

Technical Secretariat:

Miroslava Beranová
Inst. of Medical Biochemistry & Lab. Med.
First Faculty of Medicine Charles
University and General University Hosp.
U Nemocnice 2
CZ-128 08 Prague 2
phone: +420 224 962 841
fax: +420 224 962 848
e-mail: sekretariat@cskb.cz

NOMINATION COVER LETTER

10th April 2019

To:
Dr. Graham H Beastell
Chair
IFCC Nominations Committee
ifcc@ifcc.org; gbeastall@googlemail.com

Dear Dr. Beastell,

I am delighted, on behalf of the Czech Society of Clinical Biochemistry, to nominate Professor Tomáš Zima, M.D., DSc. MBA as President of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).

The Czech Society of Clinical Biochemistry (CSKB) unanimously recommended his nomination at the last CSKB Committee meeting.

Tomáš Zima has served the Czech Society of Clinical Biochemistry, the IFCC Committee and the European Federation of Clinical Chemistry and Laboratory Medical for several years.

We greatly appreciate his diligence, leadership, organizational and communication skills and especially his advocacy for clinical biochemistry both in the Czech Republic and throughout Europe.

I am convinced that Tomáš Zima will contribute significantly to the further development of the International Federation of Clinical Chemistry and Laboratory Medicine.

Yours sincerely

Richard Pikner, M.D., Ph.D.
Vice-president CSKB
IFCC and EFLM representative

Copies:
Jaroslav Racek, CSKB President
Tomáš Zima, Nominee